The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2026 | Phase I trial of INCB161734 with or without cetuximab in colorectal cancer
Jayesh Desai, MBBS, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses initial results from a Phase Ib study (NCT06179160) of INCB161734, an oral KRAS G12D inhibitor, given alone or with cetuximab, an EGFR inhibitor, in patients with advanced or metastatic colorectal cancer. Preliminary antitumour activity was encouraging with cetuximab, whilst single agent activity has been minimal with G12D inhibitors, emphasizing the need for combination strategies. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
